 |
FDA Approval Activities for this Drug
Fenofibrate Capsules (Micronized), 67 mg, Novopharm Limited ANDA 75-753 9/3/02
Fenofibrate Capsules (Micronized), 134 & 200 mg, (67 mg, strength remains ) Novopharm Limited ANDA 75-753 4/9/02 4/10/03
Fenofibrate Capsules (Micronized), 67, 134, & 200 mg, Impax, ANDA 75-868 Tricor Micro/Fenfibrate Capsules, 67 mg, Fournier Research/Abbott NDA 019-304/S-001 2/9/98 10/26/98
Tricor Indication: As an adjunctive therapy to diet for the treatment of adult patients with very high elevations of serum triglyceride levels who are at risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them.
Tricor (fenofibrate) Capsules-Micronized, Abbott NDA 19-304/S-005 4/24/00 4/27/00 6/8/01
Tricor Indication: Treatment of Hypercholesterolemia as adjunctive therapy to diet for the reduction of low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C), triglycerides, and apolipoprotein B (Apo B) in adult patients withe primary hypercholesterolemia or mixed dyslipidemia (Frederickson Types IIa and IIb).
Tricor (Fenofibrate) Tablets, 54 & 160 mg, Abbott NDA 21-203 Fenofibrate Capsules (Micronized), Impax, FENOFIBRATE Capsule; 134MG FENOFIBRATE (MICRONIZED) Teva
075753 FENOFIBRATE Capsule; 200MG FENOFIBRATE (MICRONIZED) Teva
075753 FENOFIBRATE Capsule; 67MG FENOFIBRATE (MICRONIZED) Teva
021203 FENOFIBRATE Tablet; 160MG TRICOR Abbott 021203 FENOFIBRATE Tablet; 54MG TRICOR Abbott Fenofibrate Tablets, Teva Pharmaceuticals,
Fenofibrate Tablets, Impax Pharmaceuticals, Fenofibrate Tablets, Ranbaxy Laboratories | Tricor (fenofibrate) Tablets, Abbott, Approval | Antara (Fenofibrate) Capsules, Reliant Pharma, Approval | Fenofibrate Tablets, Par Pharmaceutical, Tentative Approval | Fenofibrate Tablets, Teva Pharma, 2nd Tentative Approval | Triglide (fenofibrate) Tablets, Skye Pharma, Approval
For the most up-to-date approval information, please locate this API using the drug index.
|